Cargando…

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

[Image: see text]

Detalles Bibliográficos
Autores principales:	Foureau, David, Bhutani, Manisha, Guo, Fei, Rigby, Katherine, Leonidas, Marina, Tjaden, Elise, Fox, Andee, Atrash, Shebli, Paul, Barry, Voorhees, Peter M., Usmani, Saad Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Researcher
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525140/ https://www.ncbi.nlm.nih.gov/pubmed/34494717 http://dx.doi.org/10.1002/cam4.4254

Ejemplares similares

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)
por: Ehsan, Hamid, et al.
Publicado: (2023)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
por: Usmani, Saad Z., et al.
Publicado: (2018)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023)

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2014)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
por: Nandakumar, B., et al.
Publicado: (2022)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Postremission sequential monitoring of minimal residual disease by WT1 Q‐PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients
por: Malagola, Michele, et al.
Publicado: (2015)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
por: Atrash, Shebli, et al.
Publicado: (2023)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series
por: Atrash, Shebli, et al.
Publicado: (2017)

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
por: Ho, Caleb, et al.
Publicado: (2021)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
por: Avet-Loiseau, Hervé, et al.
Publicado: (2021)

Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma
por: Urushihara, Ryota, et al.
Publicado: (2023)

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fh9fndtiearrqbu1h52f2e65vj